Literature DB >> 23352911

Encapsulation of Nod1 and Nod2 receptor ligands into poly(lactic acid) nanoparticles potentiates their immune properties.

Vincent Pavot1, Nicolas Rochereau, Charlotte Primard, Christian Genin, Eric Perouzel, Thierry Lioux, Stéphane Paul, Bernard Verrier.   

Abstract

Most successful vaccines are able to induce persistent antibody responses that can last a lifetime. Emerging evidences indicate that activation of immune cells through pattern recognition receptors (PRRs) such as Toll-like receptors (TLRs) or Nod-like receptors (NLRs) may be critical mechanisms. Among PRRs, the use of TLR ligands as adjuvants is already largely described whereas the use of NLRs ligands remains largely unexplored. As activation of intracytoplasmic NLRs is able to induce proinflammatory molecules, the added value of encapsulation of Nod1 and Nod2 receptor ligands into Poly(Lactic Acid) (PLA) biodegradable nanocarriers to modulate their immune properties on human dendritic cells (DCs) maturation has been evaluated. Their ability to induce systemic immune responses in mice was also measured and compared to free ligands and the Alum adjuvant. Nod ligands encapsulated into PLA NPs were efficiently taken up by DCs and subsequently induced a strong up-regulation of maturation markers and the enhancement of proinflammatory cytokine secretion by DCs. Furthermore, co-injection of encapsulated Nod-ligands with PLA particles carrying Gag p24 HIV-1 antigen allowed a 100 fold increase in antibody responses in comparison to Alum. These results suggest that encapsulation of Nod ligands into PLA-NPs could be an effective way to improve vaccine efficiency.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23352911     DOI: 10.1016/j.jconrel.2013.01.015

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  26 in total

Review 1.  The Role of Nucleotide-Binding Oligomerization Domain-Like Receptors in Pulmonary Infection.

Authors:  Kristin M Wiese; Bria M Coates; Karen M Ridge
Journal:  Am J Respir Cell Mol Biol       Date:  2017-08       Impact factor: 6.914

2.  Tunable degradation of acetalated dextran microparticles enables controlled vaccine adjuvant and antigen delivery to modulate adaptive immune responses.

Authors:  Naihan Chen; Monica M Johnson; Michael A Collier; Matthew D Gallovic; Eric M Bachelder; Kristy M Ainslie
Journal:  J Control Release       Date:  2018-02-02       Impact factor: 9.776

Review 3.  Tailored immunity by skin antigen-presenting cells.

Authors:  Clement Levin; Helene Perrin; Behazine Combadiere
Journal:  Hum Vaccin Immunother       Date:  2014-11-01       Impact factor: 3.452

4.  The STING ligand cGAMP potentiates the efficacy of vaccine-induced CD8+ T cells.

Authors:  Alice Gutjahr; Laura Papagno; Francesco Nicoli; Tomohiro Kanuma; Nozomi Kuse; Mariela Pires Cabral-Piccin; Nicolas Rochereau; Emma Gostick; Thierry Lioux; Eric Perouzel; David A Price; Masafumi Takiguchi; Bernard Verrier; Takuya Yamamoto; Stéphane Paul; Victor Appay
Journal:  JCI Insight       Date:  2019-04-04

Review 5.  Unleashing the potential of NOD- and Toll-like agonists as vaccine adjuvants.

Authors:  Charles Maisonneuve; Sylvie Bertholet; Dana J Philpott; Ennio De Gregorio
Journal:  Proc Natl Acad Sci U S A       Date:  2014-08-18       Impact factor: 11.205

6.  Preparation and in vitro evaluation of imiquimod loaded polylactide-based micelles as potential vaccine adjuvants.

Authors:  Gloria Jiménez-Sánchez; Vincent Pavot; Christelle Chane-Haong; Nadège Handké; Céline Terrat; Didier Gigmes; Thomas Trimaille; Bernard Verrier
Journal:  Pharm Res       Date:  2014-09-24       Impact factor: 4.200

7.  Involvement of neutrophil hyporesponse and the role of Toll-like receptors in human immunodeficiency virus 1 protection.

Authors:  Juan C Hernandez; Diana M Giraldo; Stephane Paul; Silvio Urcuqui-Inchima
Journal:  PLoS One       Date:  2015-03-18       Impact factor: 3.240

Review 8.  Micelle-Based Adjuvants for Subunit Vaccine Delivery.

Authors:  Thomas Trimaille; Bernard Verrier
Journal:  Vaccines (Basel)       Date:  2015-09-25

9.  Poly(Lactic Acid) Nanoparticles Targeting α5β1 Integrin as Vaccine Delivery Vehicle, a Prospective Study.

Authors:  Bastien Dalzon; Célia Lebas; Gina Jimenez; Alice Gutjahr; Céline Terrat; Jean-Yves Exposito; Bernard Verrier; Claire Lethias
Journal:  PLoS One       Date:  2016-12-14       Impact factor: 3.240

Review 10.  Biodegradable Polymeric Nanoparticles-Based Vaccine Adjuvants for Lymph Nodes Targeting.

Authors:  Alice Gutjahr; Capucine Phelip; Anne-Line Coolen; Claire Monge; Anne-Sophie Boisgard; Stéphane Paul; Bernard Verrier
Journal:  Vaccines (Basel)       Date:  2016-10-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.